The Board Scenario Reinsurers Should Run on Evidence Aging

The Question a Reinsurance Board Should Be Asking About Evidence Age

Most reinsurance boards have a standing view into mortality assumption risk, catastrophe exposure, and capital adequacy. Very few have a standing view into how much of the in-force book was priced on evidence that was already going stale at the time of underwriting.

That gap is not because the risk is small. It is because nobody has framed it as a board-level scenario yet, the way mortality improvement drift or catastrophe exposure already are.

The operational fixes that reduce this exposure are covered in how better workflow design reduces underwriting evidence that ages too quickly. This post is about what the board and risk committee should be asking for, on a recurring basis, regardless of how good the operational fixes already are.

What Scenario Should the Board Actually Run?

A stress test assuming a defined percentage of the in-force book carries evidence that was already stale at the point of issuance.

This does not require perfect data to start. A reasonable first version applies a low, medium, and high staleness assumption to the current book and estimates the resulting margin and capital impact under each.

That gives the board a range to react to, rather than a single point estimate that understates uncertainty. The exercise is meant to bound the risk, not pretend to measure it with false precision.

Why Should This Be a Standing Exercise Rather Than a One-Time Review?

Because the underlying risk keeps changing shape as new evidence types and treatments emerge.

A scenario built around today's known risks, like GLP-1 medications and their effect on BMI trajectories, will miss whatever the next fast-changing evidence category turns out to be. Evidence-recency risk is not a fixed target, it is a moving one.

Running this once and filing it away treats a dynamic risk as if it were static. That mismatch is exactly how a board ends up surprised by something that, in hindsight, had been building for several renewal cycles.

What Triggers an Off-Cycle Re-Run of This Scenario?

Any development that materially changes how quickly a major evidence type can go stale.

A new class of treatment with rapid physiological effects, a shift in how cedants collect and refresh evidence, or a significant change in accelerated underwriting data sources should all trigger an off-cycle review. Waiting for the next annual cycle in these cases means the board is working from an outdated picture during exactly the period the risk is changing fastest.

What Question Should the Board Be Asking Management?

What percentage of the current book was priced on evidence older than a defined threshold, broken down by treaty duration and evidence type.

This is a more useful question than a general "is our underwriting evidence current," because it forces a specific, measurable answer rather than a reassurance. A management team that cannot answer this with real numbers is telling the board something important on its own.

The board should expect this answer to come with supporting data, not just a qualitative assurance that practices are sound. That data requirement is what turns oversight from a formality into an actual control.

How Does This Connect to Existing Risk Appetite Frameworks?

Evidence-recency risk should be an explicit line item in the underwriting risk appetite statement, not folded silently into general mortality or morbidity risk categories.

Most risk appetite statements already define tolerances for assumption drift, concentration risk, and reserve adequacy. Evidence-recency risk deserves the same explicit treatment, with its own defined tolerance and its own monitoring metric, rather than being an unnamed contributor buried inside a broader mortality risk figure.

Making it explicit is what allows the board to actually track whether the exposure is within tolerance over time, instead of relying on a general sense that underwriting practices are reasonable.

What Data Does Management Need to Bring to This Conversation?

A cohort-level breakdown of evidence age across the in-force book, plus the scenario-based margin and capital impact under a range of staleness assumptions.

This is not a request for a narrative summary. It is a request for a specific dataset, evidence age by cohort and evidence type, paired with the financial translation of what that distribution means under stress.

Tools like a Mortality Risk Scoring AI Agent can help generate the underlying cohort-level view that makes this kind of board reporting possible without a fully manual data-gathering exercise each cycle. Once that data exists, updating the board scenario becomes a repeatable process rather than a one-off project.

How Often Should This Scenario Be Re-Run?

At least annually, alongside standard actuarial assumption reviews, and immediately after any triggering development.

Tying it to the existing actuarial review cycle is a practical way to make sure it actually happens on schedule, rather than competing for attention as a separate, easily deprioritized initiative. The annual cadence also gives the board a consistent baseline to compare against year over year, which is where trend information becomes genuinely useful.

What Does a Well-Governed Response to This Risk Look Like?

A documented risk appetite statement, a standing management reporting cadence, and a scenario that gets updated and re-run rather than filed away after the first pass.

None of these three elements is sufficient on its own. A documented appetite statement without recurring reporting is just a document.

Recurring reporting without a clear appetite tolerance has no benchmark to measure against. Together, they give the board an actual, working oversight mechanism instead of a one-time exercise that quietly goes stale, in much the same way the underlying evidence it is meant to monitor does.

What Is the Cost of Not Running This Scenario at All?

The board learns about evidence-recency exposure only after it has already shown up in claims experience, at which point the affected business has already been written.

By the time a stale-evidence gap is visible in reported numbers, the cost is no longer avoidable, only manageable. The entire value of a standing board scenario is catching the exposure while it is still a modeling exercise, not a closed chapter in the loss history.

How Does This Compare to How Peer Reinsurers Approach the Same Risk?

Most peer reinsurers have not yet formalized evidence-recency risk as a named board-level scenario, which means building this capability now is a genuine differentiator, not a catch-up exercise.

Evidence-recency risk is a relatively new addition to the standard reinsurance risk taxonomy, largely because the evidence-decay dynamics driving it, like fast-acting treatments changing BMI trajectories, are themselves recent developments. A reinsurer that builds a formal scenario around this now is ahead of where most of the market currently sits, not behind an established industry standard.

That timing matters for two reasons. It gives the board a genuine competitive advantage in understanding its own book, and it gives the reinsurer a stronger position in any future regulatory or rating agency conversation where evidence-recency risk eventually becomes a standard expectation, the way mortality improvement assumption governance already has.

What Would a Rating Agency Want to See Here?

A rating agency evaluating management quality would want to see a named risk category, a documented appetite tolerance, and evidence of an actual scenario having been run, not just a policy statement.

Rating agencies increasingly assess reinsurers on the sophistication of their risk governance, not only on capital adequacy numbers. A board that can point to a specific, repeatable evidence-recency scenario, with real data behind the most recent run, is demonstrating exactly the kind of proactive governance rating agencies reward in their qualitative assessment.

Building this capability primarily to satisfy a future rating agency question would be the wrong motivation, but it is a genuine secondary benefit of doing the work for the right reason, which is actually understanding and managing the underlying exposure.

How Should This Scenario Be Presented to the Board in Practice?

The most effective presentation format is a short scenario summary, no more than a few pages, with a clear range of financial outcomes rather than a long technical report the board has to interpret on its own.

Boards respond best to material that lets them ask sharp questions quickly, not material that requires extensive background just to follow the argument. A well-built version of this scenario leads with the range of capital impact under low, medium, and high staleness assumptions, followed by the specific data behind that range, so the headline number is immediately visible rather than buried at the end of a technical appendix.

That format also makes it easier for the board to compare this scenario against other standing risk items it already reviews, like catastrophe exposure or capital adequacy stress tests, since a consistent presentation style across risk categories is what actually lets a board track trends over time rather than evaluating each report as an isolated exercise.

Risk committees that receive this kind of scenario in a familiar, comparable format tend to engage with it more directly, asking sharper follow-up questions in the same meeting rather than tabling it for a future session simply because the format itself required extra time to parse.

That is the difference between a board that is managing a known, bounded risk and one that is discovering a new one, mid-crisis, with a treaty already locked in. The reinsurers building this scenario now are choosing the first position deliberately, rather than waiting to be handed the second one by default.

Sources

• RGA: Accelerated Underwriting: Maximizing its Future
• RGA: RGA GLP-1 Study: Weighing the Evidence